Published in Br J Cancer on September 15, 2003
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer (2004) 0.88
Association between the low-dose irinotecan regimen-induced occurrence of grade 4 neutropenia and genetic variants of UGT1A1 in patients with gynecological cancers. Oncol Lett (2014) 0.75
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer (1977) 53.23
Reporting results of cancer treatment. Cancer (1981) 28.83
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med (2000) 18.12
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol (2000) 16.83
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 12.56
Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med (1999) 11.44
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med (2001) 7.59
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) J Clin Oncol (1999) 4.79
Comorbidity and functional status are independent in older cancer patients. J Clin Oncol (1998) 4.11
Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol (1999) 3.89
Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol (2002) 3.53
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol (2001) 3.21
Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ (2000) 3.09
Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer (1998) 2.94
Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol (2002) 2.51
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med (2001) 2.09
Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J Clin Oncol (2001) 2.00
Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol (1994) 1.93
Estimating the cost of informal caregiving for elderly patients with cancer. J Clin Oncol (2001) 1.92
Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med (2002) 1.89
Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol (1999) 1.59
Chemotherapy in elderly patients with colorectal cancer. Ann Oncol (2001) 1.12
Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol (1998) 1.06
General guidelines for the management of older patients with cancer. Oncology (Williston Park) (2000) 1.01
Oncology healthcare professionals' attitudes toward elderly people. Ann Oncol (2000) 0.99
Should chemotherapy be used as a treatment of advanced colorectal carcinoma (ACC) in patients over 70 years of age? Eur J Cancer (1999) 0.82
Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial. Ann Oncol (2000) 0.82
Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med (1992) 3.11
Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2. Nat Genet (2000) 2.96
Temporal lobe abnormalities on brain MRI in healthy volunteers: a prospective case-control study. Neurology (2010) 2.27
Intracranial hypertension in head injury: management and results. Intensive Care Med (1999) 2.21
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol (1999) 2.19
Intrinsic epileptogenicity of human dysplastic cortex as suggested by corticography and surgical results. Ann Neurol (1995) 2.00
Periventricular heterotopia: phenotypic heterogeneity and correlation with Filamin A mutations. Brain (2006) 2.00
The nicotinic receptor beta 2 subunit is mutant in nocturnal frontal lobe epilepsy. Nat Genet (2000) 1.73
Daily magnesium supplements improve glucose handling in elderly subjects. Am J Clin Nutr (1992) 1.65
Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol (2000) 1.59
Radiofrequency thermal ablation of 69 lung neoplasms. J Chemother (2004) 1.58
Prognostic importance of insulin-mediated glucose uptake in aged patients with congestive heart failure secondary to mitral and/or aortic valve disease. Am J Cardiol (1999) 1.56
Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer (2005) 1.55
The parkin gene is not involved in late-onset Parkinson's disease. Neurology (2001) 1.51
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol (2006) 1.47
The long-duration response to L-dopa in the treatment of early PD. Neurology (2000) 1.46
Effects of insulin on the cardiac autonomic nervous system in insulin-resistant states. Clin Sci (Lond) (2000) 1.45
Phase II study of intensive CEV (carboplatin, epirubicin and VP-16) plus G-CSF (granulocyte-colony stimulating factor) in extensive small cell lung cancer. Eur J Cancer (1995) 1.42
Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects. Diabetologia (1995) 1.42
Cerebral venous thrombosis and isolated intracranial hypertension without papilledema in CDH. Neurology (2001) 1.42
Investigator-initiated trials of targeted oncology agents: why independent research is at risk? Ann Oncol (2010) 1.41
Attention-deficit hyperactivity disorder: sometimes a disorder, often a clinical tautology. J Dev Behav Pediatr (1996) 1.38
Antiemetic activity of high-dose metoclopramide combined with methylprednisolone versus metoclopramide alone in dacarbazine-treated cancer patients. A randomized double-blind study of the Italian Oncology Group for Clinical Research. Am J Clin Oncol (1989) 1.38
cAMP-dependent phosphorylation of the nuclear encoded 18-kDa (IP) subunit of respiratory complex I and activation of the complex in serum-starved mouse fibroblast cultures. J Biol Chem (2000) 1.33
A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol (1983) 1.27
Novel SACS mutations in autosomal recessive spastic ataxia of Charlevoix-Saguenay type. Neurology (2004) 1.26
Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol (2003) 1.25
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol (2005) 1.24
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol (2009) 1.24
Human placental neuraminidase. Activation, stabilization and association with beta-galactosidase and its protective protein. Eur J Biochem (1985) 1.23
Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol (2005) 1.22
Total-body and myocardial substrate oxidation in congestive heart failure. Metabolism (1994) 1.19
Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev (2010) 1.19
Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol (1999) 1.17
Prevention of endemic canine vector-borne diseases using imidacloprid 10% and permethrin 50% in young dogs: a longitudinal field study. Vet Parasitol (2010) 1.16
Targeting EGFR in pancreatic cancer treatment. Curr Drug Targets (2012) 1.15
Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha. Am J Physiol (1998) 1.15
Characterization of ligurian melanoma families and risk of occurrence of other neoplasia. Int J Cancer (1999) 1.13
Glucose tolerance and insulin action in healty centenarians. Am J Physiol (1996) 1.13
Localization of a gene responsible for autosomal recessive demyelinating neuropathy with focally folded myelin sheaths to chromosome 11q23 by homozygosity mapping and haplotype sharing. Hum Mol Genet (1996) 1.13
Alteration of the in vivo nicotinic receptor density in ADNFLE patients: a PET study. Brain (2006) 1.11
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer (2006) 1.09
Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol (1997) 1.09
Cyclic adenosine monophosphate-dependent phosphorylation of mammalian mitochondrial proteins: enzyme and substrate characterization and functional role. Biochemistry (2001) 1.08
The use of external fixators in femur fractures in children. J Pediatr Orthop (1997) 1.07
PAX6 mutation in a family with aniridia, congenital ptosis, and mental retardation. Clin Genet (2001) 1.07
Autosomal recessive hereditary motor and sensory neuropathy with focally folded myelin sheaths: clinical, electrophysiologic, and genetic aspects of a large family. Neurology (1996) 1.07
Cimetidine and psoriasis. Lancet (1978) 1.07
Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer (1989) 1.06
Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology (1999) 1.05
Multihance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol (1998) 1.05
Hippocampal and thalamic atrophy in mild temporal lobe epilepsy: a VBM study. Neurology (2008) 1.04
Serum levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in healthy centenarians: relationship with plasma leptin and lipid concentrations, insulin action, and cognitive function. J Clin Endocrinol Metab (1997) 1.03
Does free fatty acid infusion impair insulin action also through an increase in oxidative stress? J Clin Endocrinol Metab (1996) 1.02
Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer (2001) 1.02
Plasma leptin concentrations and cardiac autonomic nervous system in healthy subjects with different body weights. J Clin Endocrinol Metab (2000) 1.02
MRI evidence of mesial temporal sclerosis in sporadic "benign" temporal lobe epilepsy. Neurology (2006) 1.02
Characterization of the sialidase molecular defects in sialidosis patients suggests the structural organization of the lysosomal multienzyme complex. Hum Mol Genet (2000) 1.01
Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. J Clin Oncol (1988) 1.01
Nuclear changes in a case of X-linked Emery-Dreifuss muscular dystrophy. Muscle Nerve (1999) 1.00
Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Ann Oncol (1997) 0.99
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. Ann Oncol (2008) 0.99
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene (2007) 0.99
Loss of long-duration response to levodopa over time in PD: implications for wearing-off. Neurology (1999) 0.99
Effect of metformin on food intake in obese subjects. Eur J Clin Invest (1998) 0.99
Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes. Diabetologia (1998) 0.98
Association of fasting plasma free fatty acid concentration and frequency of ventricular premature complexes in nonischemic non-insulin-dependent diabetic patients. Am J Cardiol (1997) 0.98
SCARB2 mutations in progressive myoclonus epilepsy (PME) without renal failure. Ann Neurol (2009) 0.98
Molecular mechanisms for the hepatic uptake of magnetic resonance imaging contrast agents. Biochem Biophys Res Commun (1999) 0.98
Sorafenib: from literature to clinical practice. Ann Oncol (2013) 0.98
KEYnet: a keywords database for biosequences functional organization. Nucleic Acids Res (1999) 0.97
Ultrastructural markers of quality in human mature oocytes vitrified using cryoleaf and cryoloop. Reprod Biomed Online (2009) 0.97
Studies on hemophilia A in Sardinia bearing on the problems of multiple allelism, carrier detection, and differential mutation rate in the two sexes. Am J Hum Genet (1984) 0.96
The fragile X premutation presenting as postprandial hypotension. Neurology (2004) 0.95
Vitamin E deficiency due to chylomicron retention disease in Marinesco-Sjögren syndrome. Ann Neurol (2000) 0.95
Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. Eur J Cancer (2001) 0.95
Cellular labeling with Gd(III) chelates: only high thermodynamic stabilities prevent the cells acting as 'sponges' of Gd3+ ions. Contrast Media Mol Imaging (2006) 0.94
Permeability of human oocytes to ethylene glycol and their survival and spindle configurations after slow cooling cryopreservation. Hum Reprod (2007) 0.94
Metabolic benefits deriving from chronic vitamin C supplementation in aged non-insulin dependent diabetics. J Am Coll Nutr (1995) 0.94
Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer (1997) 0.94
The role of lymphatic stasis in Kaposi's sarcoma onset. G Ital Dermatol Venereol (2014) 0.94
Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG). Ann Oncol (2001) 0.94
Relationship between atrophy of the amygdala and ictal fear in temporal lobe epilepsy. Brain (1994) 0.93
Galactosialidosis: molecular heterogeneity among distinct clinical phenotypes. Am J Hum Genet (1986) 0.93